tumor tissue News
-
SurgiMab advances SGM-101 into pivotal Phase 3 clinical trial to improve surgical outcomes in colorectal cancer patients
SurgiMab, a late-stage biotechnology company pioneering a new antibody-based fluorescence-guided approach designed to improve cancer surgery and clinical outcomes for patients, today announces that the first surgical procedure was carried out in a pivotal Phase 3 clinical trial of the Company's lead product, SGM-101, in a patient with colorectal cancer (CRC). SGM-101 is a tumor-specific antibody ...
By SurgiMab
-
SurgiMab announces recruitment of first US patient in pivotal Phase 3 clinical trial evaluating SGM-101 in colorectal cancer patients
SurgiMab, a late-stage biotechnology company pioneering a new antibody-based fluorescence-guided approach with the aim to improve cancer surgery and clinical outcomes for patients, today announces that the first US patient has been recruited into its on-going pivotal Phase 3 clinical trial evaluating its investigational imaging agent SGM-101 in patients undergoing colorectal cancer (CRC) surgery. ...
By SurgiMab
-
CIS Pharma demonstrates successful in-vivo biodistribution study for Oncology drug carrier
CIS Pharma successfully completed the biodistribution study with its polymer carrier technology applied to an antibody radionuclide conjugate (ARC). The conjugate was tested in a SKOvip mouse model, an aggressive form of ovarian cancer. The ARC tested comprised Trastuzumab as a model antibody to which two polymer carriers were conjugated that contained several chelators for the immobilization of ...
-
Lixte Biotechnology Holdings, Inc. Announces that enrollment has resumed in national cancer institute’s trial to determine ability of Lixte compound lb-100 to enter recurrent, malignant brain tumors
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) announced that the National Cancer Institute (NCI) has resumed enrolling patients into their pharmacologic study of the ability of Lixte’s lead compound, LB-100, to enter the brain and penetrate recurrent, malignant brain tumors, in patients where surgical removal of their cancer is indicated. After enrolling two patients in the study, ...
-
AI Helps Improve Tumor Diagnosis in the Operating Room
To help neurosurgeons diagnose brain tumors more efficiently, researchers from the University of Michigan developed a deep learning-based imaging technique that can reduce the tumor diagnosis process during surgery from 30-40 minutes to less than three minutes. First unveiled in 2017, the technique called stimulated Rama histology (SRH) helps neurosurgeons more rapidly assess tumor tissue in ...
-
Xilis Presents Data at ESMO 2021 Demonstrating Capabilities of MicroOrganoSphere Technology for Cancer Drug Screening
Data suggests MOS platform recapitulates primary tumor tissue heterogeneity, including genomic and transcriptomic features, and microenvironment, comprising immune and stromal components MOS can be used in the evaluation of cancer drug response for chemotherapies and immunotherapies in the research setting Xilis, Inc., a pioneering company developing its MicroOrganoSphere (MOS) technology ...
By XILIS, Inc.
-
Application of Whole-Genome Sequencing in Older Esophageal Carcinoma FFPE Tissues Reveals Novel Insights
Collection of fresh-frozen tumor samples is often challenging or infeasible, leading many studies to rely on formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples. Because these tissues are often paired with a great deal of clinical and outcome data, analysis of these archives has the potential to lead to major advances in cancer treatment and prevention. Whole-genome sequencing (WGS) ...
-
SurgiMab and Quest Medical Imaging announce Collaboration Agreement for phase III Clinical Trial
SurgiMab and Quest Medical Imaging, a leader in the market for multispectral cameras, announced today that they have entered into a collaboration agreement for the upcoming Phase III clinical trial of Surgimab’s SGM-101 in fluorescent guided colorectal cancer surgery. Under the terms of the agreement, Quest Medical Imaging has received an undisclosed lump sum payment to provide 12 ...
By SurgiMab
-
Reflections from 4D Path’s HER2 and Ki67 Publications
4D Path recently had the honor of including two publications in the virtual curriculum at the 2022 ASCO Annual Meeting. The publications addressed that the majority of druggable targets that drive oncogenic vulnerability are not expressed in a uniform or homogeneous manner throughout tumor tissue. Thus, intratumoral heterogeneity, as observed among the cells of an individual ...
By 4D Path Inc.
-
Foundation Medicine Now an In-Network Provider for Humana Military and Health Net Federal Services
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc. today announced that the company has signed agreements for in-network provider status with Humana Military and Health Net Federal Services, which administer the TRICARE health program for military members, retirees and their families (TRICARE).1,2 TRICARE is one of the largest health plans in the United States with 9.6 million ...
-
Foundation Medicine Announces Global Collaboration With Lilly to Develop FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for RETEVMO® and Loxo Oncology at Lilly’s Pipeline Programs
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc. today announced a collaboration with Eli Lilly and Company (Lilly) for the development of Foundation Medicine’s tissue- and blood-based assays as companion diagnostics for RETEVMO® and other therapies in Loxo Oncology at Lilly’s pipeline. The partnership will initially explore the use of FoundationOne®CDx for adult ...
-
Hummingbird Diagnostics Announces Publication of Study on the Utility of miRisk, a Blood-based microRNA Analysis, to Predict Overall Survival for Advanced Non-Small Cell Lung Cancer in npj Precision Oncology
Results describe development of analysis to uncover association of several microRNAs with overall survival following initiation of immunotherapy. Blood-based test holds potential for broad applicability for the management of patients with cancer. Hummingbird Diagnostics GmbH, a leader in reading blood-based microRNAs for early disease detection and characterization, today announced the ...
-
Calviri Awarded NCI Grant for the Development of a New Blood Test That May Predict Responders to Checkpoint Inhibitor Therapies
Calviri, Inc., a start-up focused on ending deaths from cancer through unconventional approaches to diagnostics and vaccines, was recently awarded a $300,000 Phase I grant through the Small Business Innovation Research Program (SBIR) at the National Cancer Institute (NCI). This one-year grant will support the development of a new test for establishing whether a cancer patient’s tumor has ...
By Calviri
-
BOC Sciences Unveils Comprehensive Capabilities of Custom Peptide Drug Conjugate
BOC Sciences, a leading CRO in the USA, unveils its comprehensive capabilities for custom peptide drug conjugate from project design to commercial production. With its well-established conjugation platform, BOC Sciences supports pharmaceutical and biotechnology clients at the forefront of drug conjugation. Peptide-drug conjugates (PDCs) are mainly used in anti-cancer therapy, which integrates the ...
By BOC Sciences
-
Profacgen Updated Its E3 Ligase and Target Proteins Development Services
Profacgen has recently updated its E3 Ligase and Target Proteins Development Services, expanding the company’s portfolio of PROTAC development services. The updated services provide scientists with comprehensive advanced platform for their projects. The ubiquitin proteasome system relies heavily on E3 ligases (UPS). As a major modulator of protein homeostasis, UPS is essential in signal ...
By Profacgen
-
Creative Biolabs Upgrades Oncolytic Virus Product List for Immunotherapy Research
As early as around 1800, doctors discovered that certain cancer patients would have their symptoms reduced after being briefly infected with viruses. With the advancement of genetic engineering technology, the idea that viruses have the potential to improve and mediate immunotherapy has been established. Oncolytic viruses (OVs) are such kind of viruses that can replicate in tumor tissues, and ...
-
Thermo Fisher Scientific Expands GlobalAccess Sequencing Program
Thermo Fisher Scientific today announced the expansion of its GlobalAccess Sequencing Program to include laboratories working in oncology. Originally introduced to accelerate multi-institutional-led studies focused on SARS-CoV-2, the expanded program now provides support to labs facing significant constraints as a result of the global pandemic by offering faster access to comprehensive, ...
-
FDA Approves NGS-Based Companion Diagnostic for EGFR Exon20 Insertion Mutant Non-Small Cell Lung Cancer Tumor Tissue
The U.S. Food and Drug Administration (FDA) has granted premarket approval to Thermo Fisher Scientific's Oncomine Dx Target Test as a companion diagnostic (CDx) to help identify non-small cell lung cancer (NSCLC) patients whose tumors carry epidermal growth factor receptor (EGFR) Exon20-insertion mutations for potential treatment with RYBREVANT (amivantamab-vmjw)*, Janssen Biotech, Inc.'s ...
-
TAE Life Sciences Identifies Proprietary Drug Candidates to Support Boron Neutron Capture Therapy (BNCT)
Drugs being developed to expand indications for treatment and improve efficacy of BNCT for cancer treatment Only company developing comprehensive new target drug portfolio and accelerator-based neutron system TAE Life Sciences (TLS), a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced that as part of its growing ...
-
NeoTherma Oncology Announces FDA IDE Submission to Permit Investigational Treatment of Pancreatic Cancer Patients with Its FDA-Designated Breakthrough Device, the VectRx Thermal Oncology System
NeoTherma Oncology, (NTO) a privately held medical device company developing novel non-invasive treatments for solid tumors, today announces they have submitted an Investigational Device Exemption (IDE) application to the Food and Drug Administration (FDA) to initiate First-in-Human (FiH) studies of the VectRx™ System in patients with pancreatic cancer being treated with standard of care ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you